Eli Lilly and Company
LLY
$1015.75
+2.61%
Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing medicines across key therapeutic areas including cardiometabolic health, immunology, neuroscience, and oncology. The company is a dominant market leader, particularly distinguished as a pioneer and volume leader in the massively expanding GLP-1 agonist market for diabetes and obesity with its blockbuster drugs Mounjaro and Zepbound. The current investor narrative is overwhelmingly centered on its execution in the weight-loss drug market, with recent headlines highlighting a significant earnings beat, a raised 2026 outlook, and the FDA approval of a convenient oral GLP-1 drug, Foundayo, which is seen as widening its competitive moat, though early prescription data for the pill has also introduced some volatility.…
LLY
Eli Lilly and Company
$1015.75
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating & Thesis: Hold. Eli Lilly is a fundamentally exceptional company executing flawlessly in a generational growth market, but its premium valuation and recent technical weakness warrant patience for a better entry point. This is consistent with the overwhelmingly bullish analyst sentiment but tempers it with valuation discipline.
Supporting Evidence: The company's financials are stellar, with 42.6% YoY revenue growth, a 34.4% net margin, and $8.97B in TTM free cash flow. The forward P/E of 22.29x, based on estimated EPS growth to $60.89, implies the market is pricing in near-doubling earnings. However, the current trailing P/E of 46.76x and P/S of 14.81x are at a significant premium to the pharmaceutical industry, demanding perfection. The implied 41% upside to the average analyst target is compelling but requires growth to meet lofty forecasts.
Risks & Conditions: The two biggest risks are valuation multiple compression and growth deceleration in the core GLP-1 franchise. This Hold rating would upgrade to a Buy if the stock experiences a further correction towards a forward P/E of ~20x (implying a price near $1,218) or if quarterly revenue growth re-accelerates above 45% YoY. It would downgrade to Sell if revenue growth decelerates below 30% YoY or if the debt-to-equity ratio rises above 2.0. Relative to its own growth trajectory and peer group, the stock is fairly valued to slightly overvalued at current levels, baking in significant future success.
Sign up to view all
LLY 12-Month Price Forecast
The outlook is bifurcated between stellar fundamentals and a demanding valuation. The base case (55% probability) sees the stock appreciating towards the analyst average target of ~$1,357 as earnings grow into the valuation, but this path requires flawless execution. The bear case, while lower probability, carries significant downside risk to the $850 support level if growth stumbles. The stance would upgrade to Bullish on a conclusive breakout above the all-time high of $1,133.95 on strong volume, confirming the primary uptrend has resumed. It would downgrade to Bearish on a sustained break below the recent low of $851.21, signaling a deeper correction and potential growth concerns.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1320.48 and implied upside of +30.0% versus the current price.
Average Target
$1320.48
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$813 - $1320
Analyst target range
Analyst coverage is robust with 11 firms providing estimates, indicating strong institutional interest. The consensus sentiment is overwhelmingly bullish, as evidenced by recent institutional actions where firms like Guggenheim, Deutsche Bank, JP Morgan, and Morgan Stanley have maintained Buy or Overweight ratings. The average target price is derived from estimated metrics; the average EPS estimate is $60.89, which, applied to the forward PE of 22.29x, implies a consensus price target of approximately $1,357, representing a substantial +41% upside from the current price of $963.33. The target range, inferred from EPS estimates, is wide, with a low EPS of $54.51 and a high of $65.26, translating to price targets of roughly $1,215 and $1,455, respectively. The high target assumes flawless execution, continued demand surge for GLP-1 drugs, and successful pipeline advancements, while the low target likely factors in potential competition, pricing pressures, or clinical setbacks. The wide spread signals healthy debate and uncertainty about the precise trajectory, though the bullish skew of recent ratings (with only one Reduce rating from HSBC in March) underscores strong conviction in the long-term story.
Bulls vs Bears: LLY Investment Factors
The bull case, anchored in explosive 42.6% revenue growth, expanding 34.4% net margins, and a 41% analyst target upside, currently holds stronger evidence. However, the bear case presents a formidable counter-argument centered on a vulnerable premium valuation (46.76x trailing P/E) and recent technical deterioration. The single most important tension in the investment debate is whether the company's phenomenal growth can sustain long enough to justify and grow into its current valuation, or if inevitable growth deceleration will trigger a painful multiple compression. The stock's fate hinges on the quarterly trajectory of GLP-1 sales versus increasingly high market expectations.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 42.6% year-over-year to $19.29 billion, driven by the dominant GLP-1 franchise. Sequential quarterly acceleration from $12.73B to $19.29B demonstrates powerful demand momentum for Mounjaro and Zepbound.
- Exceptional Profitability & Margins: The company exhibits superior profitability with a Q4 net margin of 34.4% and a gross margin of 85.05%. This operational leverage is reflected in a staggering Return on Equity of 77.78%, indicating immense efficiency in generating shareholder returns.
- Strong Analyst Conviction & Upside: Analyst consensus implies a price target of ~$1,357, representing 41% upside from the current price. The bullish sentiment is underpinned by an average forward EPS estimate of $60.89 and a forward P/E of just 22.29x, signaling high growth expectations.
- Pipeline & Competitive Moat Widening: Recent FDA approval of the oral GLP-1 drug Foundayo provides a significant competitive advantage and convenience factor. This, coupled with a raised 2026 outlook, solidifies Lilly's leadership in the massive obesity and diabetes market.
Bearish
- Premium Valuation at Risk: The trailing P/E of 46.76x and P/S of 14.81x represent a significant premium to typical large-cap pharma peers. This lofty valuation leaves the stock vulnerable to multiple compression if revenue growth decelerates from the current 42.6% YoY rate.
- Recent Technical & Momentum Weakness: The stock is down 7.12% over the past 3 months and has underperformed the SPY by -11.26% in that period, signaling a loss of momentum. Trading at 61% of its 52-week range suggests a corrective phase after a powerful rally.
- High Leverage & Execution Dependency: A debt-to-equity ratio of 1.60 indicates significant financial leverage. The company's ability to service this debt and fund growth is entirely dependent on the continued flawless execution and commercial success of its GLP-1 franchise.
- Competitive & Early Pipeline Volatility: News of disappointing early prescription data for the new oral drug Foundayo introduced stock volatility. The market remains highly sensitive to any signs of competitive pressure from Novo Nordisk or emerging players like Viking Therapeutics.
LLY Technical Analysis
The stock is in a sustained long-term uptrend but has recently entered a corrective phase. With a 1-year price change of +21.31%, the trend is positive, but the current price of $963.33 sits at approximately 61% of its 52-week range ($623.78 to $1133.95), indicating a retreat from recent highs and positioning the stock in the middle of its annual band, suggesting a period of consolidation after a powerful rally. Recent momentum has diverged sharply from the longer-term trend, turning negative. The stock is down 7.12% over the past 3 months and up a modest 0.92% over the past month, significantly underperforming the SPY, which gained 4.14% and 9.98% over the same periods, respectively. This negative relative strength of -11.26% over 3 months signals a loss of momentum and potential profit-taking or rotation away from the name. Key technical support is anchored at the 52-week low of $623.78, while immediate resistance is at the 52-week high of $1133.95. A breakdown below the recent low of $851.21 (from April 29, 2026) could signal a deeper correction, while a breakout above the all-time high would reaffirm the primary bull trend. The stock's beta of 0.504 indicates it is approximately 50% less volatile than the broader market, which is unusually low for a growth-oriented biopharma and may reflect its massive scale and perceived defensive characteristics.
Beta
0.48
0.48x market volatility
Max Drawdown
-30.4%
Largest decline past year
52-Week Range
$624-$1134
Price range past year
Annual Return
+36.1%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +9.3% | +8.2% |
| 3m | -2.2% | +9.0% |
| 6m | -0.9% | +10.5% |
| 1y | +36.1% | +26.5% |
| ytd | -6.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is explosive and accelerating, driven by the GLP-1 franchise. Q4 2025 revenue was $19.29 billion, representing a staggering 42.6% year-over-year growth. Sequentially, revenue has grown from $12.73 billion in Q1 2025 to $19.29 billion in Q4, demonstrating powerful quarterly acceleration, with the Cardiometabolic segment (housing Mounjaro and Zepbound) contributing $13.18 billion in the latest period. Profitability is robust and margins are expanding significantly. Net income for Q4 2025 was $6.64 billion, with a net margin of 34.4%. Gross margin was exceptionally high at 85.05% for the quarter, and the trailing twelve-month operating margin stands at 45.56%. Comparing Q4 2025 to Q4 2024, net income surged from $4.41 billion to $6.64 billion, and the net margin expanded from 32.6% to 34.4%, illustrating both top-line leverage and operational efficiency. The balance sheet is leveraged but cash generation is strong. The debt-to-equity ratio is elevated at 1.60, indicating significant leverage used to fund growth and potentially share buybacks. However, the company generates substantial cash, with TTM free cash flow of $8.97 billion. Return on Equity is exceptionally high at 77.78%, reflecting immense profitability on shareholder capital, while the current ratio of 1.58 suggests adequate short-term liquidity to meet obligations.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given a positive net income of $6.64 billion, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 46.76x, while the forward PE is significantly lower at 22.29x. This substantial gap implies the market is pricing in extremely high earnings growth expectations for the coming year, anticipating a near-doubling of EPS. Compared to industry averages, Eli Lilly trades at a significant premium. Its trailing PE of 46.76x and Price-to-Sales ratio of 14.81x are well above typical sector multiples for large-cap pharmaceuticals, which often trade in the mid-teens to low-20s PE range. This premium is justified by the company's superior growth profile, with 42.6% YoY revenue growth and dominant positioning in the high-conviction obesity market, which most peers cannot match. Historically, the stock's own valuation is near the upper end of its range. The current trailing PE of 46.76x is above the historical median seen in recent quarters (e.g., 30.65x in Q3 2025, 39.28x in Q4 2024) but below extreme peaks like 67.20x in Q1 2025. This suggests the market is pricing in optimistic, but not peak, expectations, leaving room for multiple compression if growth decelerates or fails to meet lofty forecasts.
PE
46.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Eli Lilly's primary financial risk is its elevated leverage, with a debt-to-equity ratio of 1.60, which amplifies financial risk if growth stalls. While cash generation is strong ($8.97B TTM FCF), the company faces significant concentration risk, with the Cardiometabolic segment (GLP-1 drugs) driving the majority of its 42.6% YoY revenue growth. Any disruption in this franchise would immediately pressure the high net margin of 34.4%. Furthermore, the business model is dependent on continuous heavy R&D investment to sustain the pipeline, creating operational execution risk.
Market & Competitive Risks: The stock trades at a substantial premium to sector norms (46.76x trailing P/E vs. typical pharma mid-teens), creating high valuation compression risk if growth expectations are not met. Competitive threats are intensifying, with Novo Nordisk as a direct rival and promising candidates from firms like Viking Therapeutics generating bullish analyst coverage. The stock's low beta of 0.504 suggests it is not highly correlated with the broader market, but it is highly sensitive to company-specific news, as seen with volatility following Foundayo prescription data. Sector rotation away from high-growth, high-multiple stocks poses a macro risk.
Worst-Case Scenario: A worst-case scenario involves a combination of faster-than-expected competitive encroachment, manufacturing issues limiting GLP-1 supply, and a clinical setback in the pipeline. This could trigger a simultaneous earnings miss and a severe derating of the valuation multiple. Realistic downside could see the stock re-testing its 52-week low of $623.78, which would represent a loss of approximately -35% from the current price of $963.33. The historical max drawdown of -30.4% provides a recent benchmark for potential volatility in a severe adverse scenario.
FAQ
The key risks are: 1) Valuation Risk: High multiples (46.76x P/E) are vulnerable to compression if growth slows. 2) Competitive Risk: Intense rivalry from Novo Nordisk and emerging biotechs like Viking Therapeutics. 3) Concentration Risk: Over-reliance on the GLP-1 franchise, which drove $13.18B of Q4's $19.29B revenue. 4) Financial Risk: Elevated debt-to-equity ratio of 1.60, though mitigated by strong cash flow. Of these, valuation and concentration risks are the most severe, as they are intertwined and could trigger a simultaneous earnings and multiple disappointment.
The 12-month forecast presents three scenarios. The Base Case (55% probability) targets $1,215-$1,357, assuming the company meets consensus EPS estimates and the forward P/E holds. The Bull Case (30% probability) targets $1,455-$1,550+ on flawless execution and pipeline wins. The Bear Case (15% probability) sees a drop to $850-$1,050 on growth deceleration and multiple compression. The most likely outcome is the Base Case, anchored by the analyst average target, but it requires the company to maintain its current blistering growth pace to justify the valuation.
LLY is fairly valued to slightly overvalued based on traditional metrics but may be reasonably valued on forward estimates. Its trailing P/E of 46.76x and Price-to-Sales of 14.81x are at a large premium to the pharmaceutical sector. However, the forward P/E of 22.29x, based on expected EPS of $60.89, reflects the market's anticipation of nearly doubling earnings. The valuation implies the market is paying for near-perfect execution of its GLP-1 growth story. Any stumble would likely cause the multiple to compress towards sector averages.
LLY is a good buy for investors seeking exposure to a dominant player in a secular growth market, but timing is crucial. The stock offers a compelling 41% implied upside to the average analyst target of ~$1,357, backed by explosive 42.6% revenue growth. However, its premium valuation (46.76x trailing P/E) introduces significant risk if growth decelerates. It is a good buy for long-term, conviction-driven investors willing to hold through volatility, but tactical investors may prefer to wait for a better entry point during market pullbacks.
LLY is primarily suitable for a long-term investment horizon of 3-5 years. While its low beta of 0.504 suggests lower volatility than the market, its recent price action shows high sensitivity to company-specific news, making it challenging for short-term trading. The investment thesis is based on the multi-year expansion of the obesity drug market and Lilly's execution within it, which will take time to fully play out. The minimal dividend yield of 0.56% further indicates this is a growth, not an income, stock. A minimum holding period of 18-24 months is suggested to weather potential volatility and allow the growth narrative to unfold.